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Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) induced by myelin
oligodendrocyte protein (MOG) in female Dark Agouti (DA) rats is a chronic demyelinating animal
model of multiple sclerosis (MS). To identify new candidate molecules involved in the evolution or
repair of EAE-lesions we used Affymetrix oligonucleotide microarrays to compare the spinal cord
transcriptome at the peak of EAE, during remission and at the first relapse with healthy DA rats.
Methods: Untreated DA rats and DA rats immunised with MOG protein were sacrificed at
defined time points. Total RNA was isolated from spinal cord tissue and used for hybridization of
Affymetrix rat genome arrays RG U34 A-C. Selected expression values were confirmed by
RealTime PCR.
Adult neural stem cells were incubated with recombinant secretory leukocyte protease inhibitor
(SLPI). Proliferation was assessed by BrdU incorporation, cyclin D1 and HES1 expression by
RealTime PCR, cell differentiation by immunofluorescence analysis and IkappaBalpha degradation
by Western blot.
Results: Among approximately 26,000 transcripts studied more than 1,100 were differentially
regulated. Focussing on functional themes, we noticed a sustained downregulation of most of the
transcripts of the cholesterol biosynthesis pathway. Furthermore, we found new candidate genes
possibly contributing to regenerative processes in the spinal cord. Twelve transcripts were solely
upregulated in the recovery phase, including genes not previously associated with repair processes.
Expression of SLPI was upregulated more than hundredfold during EAE attack. Using
immunohistochemistry, SLPI was identified in macrophages, activated microglia, neuronal cells and
astrocytes. Incubation of adult neural stem cells (NSC) with recombinant SLPI resulted in an
increase of cell proliferation and of differentiation towards oligodendrocytes. These processes
were paralleled by an upregulation of the cell-cycle promotor cyclin D1 and a suppression of the
cell differentiation regulator HES1. Finally, SLPI prevented the degradation of IkappaBalpha, which
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mechanism of oligodendroglial differentiation.
Conclusion: We identified novel features of gene expression in the CNS during EAE, in particular
the suppression of genes of cholesterol biosynthesis and a strong upregulation of SLPI, a gene which
is for the first time associated with autoimmune inflammation. The capacity of SLPI to increase
proliferation of adult NSC and of oligodendroglial differentiation suggests a novel role for SLPI in
the promotion of tissue repair, beyond its known functions in the prevention of tissue damages by
protease inhibition damage and modulation of inflammatory reactions.
Background
Experimental autoimmune encephalomyelitis (EAE) rep-
resents a variety of animal models reflecting clinical and
pathological characteristics of multiple sclerosis (MS). MS
is presumably a autoimmune CNS disease with stepwise
or chronic progressive evolution of inflammation, demy-
elination, axonal injury and oligodendrocyte death inter-
twined with the nervous system's attempts to repair
damage and regain homeostasis. The complexity of these
processes remains a formidable obstacle to the elucida-
tion of the primary and driving pathogenetic events [1].
Transcriptome studies of CNS tissue in MS and EAE prob-
ing many thousand gene products in parallel have
resulted in interesting and unexpected target molecules
possibly suitable for therapeutic trials in MS [2,3]. Most
studies describing the transcriptional spinal cord profile
in EAE have been performed in murine models [4-9]. EAE
induced by myelin oligodendrocyte protein (MOG) in the
rat represents a spectrum of diseases mimicking various
forms of MS pathology depending on the selection of
strain, gender and experimental procedures, respectively.
In female Dark agouti (DA) rats, a chronic relapsing EAE
variant can be induced, characterized by widespread
demyelination, axonal damage and remyelination [10].
MOG has been recognized as a particularly likely candi-
date for an initial antigen-specific attack in the CNS dur-
ing MS, and T- and B-cell responses to MOG have been
identified in MS-patients and in EAE [11-13]. This report
presents for the first time spinal cord transcriptional data
of a chronic EAE model in the rat. We compared the
mRNA expression profile of more than 26,000 transcripts
in spinal cords of DA rats by a large scale gene expression
approach using the DNA microarray technique. Expres-
sion profiling from spinal cord tissue comparing rats with
EAE and healthy control rats was performed in three dis-
tinct stages of disease evolution, i.e. acute, recovery and
relapsing phases of EAE. More than 1,100 significantly
regulated transcripts were identified. While confirming
well-established features of EAE, we identified several dif-
ferentially upregulated transcripts not described previ-
ously. In more detail, we examined the secretory leukocyte
protease inhibitor (SLPI) representing the most strongly
upregulated gene in this study. SLPI is a homeostatic pro-
tein known to be expressed at mucosal surfaces by epithe-
lial cells, macrophages and neutrophils. It is involved in
the resolution of inflammation by suppressing protease
activity, by attenuating innate immune responses and by
inhibiting the activation and proliferation of B cells
[14,15]. In the CNS its induction has been reported as a
consequence of ischemic stroke [14] and spinal cord
injury [16]. In this study we provide evidence that SLPI
promotes oligodendroglial proliferation and differentia-
tion. We suggest that SLPI may have a novel and multiple
roles in CNS inflammation, i.e. inhibition of pathogenic




Female dark agouti (DA) rats, 6–8-week old, were pur-
chased from Harlan Winkelmann. They were housed in
the animal facility of the University of Regensburg and
were 8–10-weeks old when used for the experiments. All
procedures were conducted according to protocols
approved by the animal care committee of the Medical
Faculty.
Induction and clinical evaluation of EAE
For the microarray experiment 20 female DA rats were
immunized intradermally at the base of the tail with 65 μg
MOG(aa 1–125) emulsified in complete Freund's adju-
vant (CFA) containing 400 μg of heat-inactivated Myc.
tuberculosis (H37Ra, (DIFCO)) in a total volume of 200 μl.
Animals were weighed and scored daily for signs of EAE
according to the following scale: 0, no disease; 1, tail
paralysis; 2, hind limb weakness; 3, hind limb paralysis; 4,
hind limb paralysis plus forelimb weakness; 5, moribund
or dead. The mean cumulative score for a treatment group
was calculated as the sum of the daily scores of all animals
from day zero until the end of the experiment divided by
the number of animals in the respective group.
Microarrays
The Affymetrix GeneChip Rat Genome U34 Arrays A, B and
C were used for this study. They represent more than
26,000 genes currently consisting of approximately 8,000Page 2 of 20
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(ESTs).
Sample preparation and hybridization
DA rats were perfused with PBS to remove circulating
blood cells and their spinal cords and inguinal lymph
nodes were collected. Total RNA was extracted from lum-
bar spinal cords and lymph nodes, respectively, using the
RNeasy Lipid Tissue Midi Kit (Qiagen) and examined for
signs of degradation with the Bioanalyzer 2100 (Agilent
Technologies). All further preparation steps were per-
formed at the "Centre of Excellence for Fluorescent Bioan-
alytics" (KFB, Regensburg, Germany). Isolated RNA was
processed according to the standard Affymetrix protocol.
Hybridization, washing and staining of Affymetrix rat
U34 arrays were carried out following manufacturer's
instructions. In brief, double stranded cDNA was gener-
ated from 10 μg RNA with the Superscript Double-
Stranded cDNA Synthesis Kit (Invitrogen). The High Yield
RNA Transcript Labeling Kit (Enzo Life Sciences) was used
to obtain biotinylated cRNA. The three Affymetrix arrays
RG U34A-C were consecutively hybridised with the sam-
ples in a rotating chamber (16 h, 45°C). The arrays were
scanned by the G2500A GeneArray Scanner (Affymetrix).
Data analysis
Hybridization patterns were processed and quantified
using MAS 5.0 software. Parameters for the assessment of
the hybridization quality included the signal-to-noise
ratio, signal spreading, average signal intensity and the
ratio between the 5' and 3'ends of the house keeping
genes actin and GAPDH. Empirical cut-off values were set
for these criteria and samples not meeting them were
excluded from further analysis.
Transcripts labelled absent by the dchip 2006 algorithm
[17] in more than 80% of the samples were also not sub-
jected to further analysis. Animals from the different dis-
ease phases were compared with healthy control animals
using dchip 2006. Significantly regulated transcripts had
to meet the following criteria: (a) a mean signal ratio > 2
between groups of arrays [6,18-20] and (b) a p-value <
0.01 according to an unpaired t-test.
A functional analysis combined with an extraction of
overrepresented functional gene groups was performed
using the NetAffx-software (Affymetrix, [21]) and the
EASE program [22]. Principal component analyses based
on the hybridization results from the RG U34A chips were
performed using BRB ArrayTools developed by Dr. Rich-
ard Simon and Amy Peng Lam (NIH, USA, [23]).
Data accession
All data are available online through Array Express (acces-
sion number E-MEXP-1025).
Determination of transcripts expressed in the inflamed 
CNS but not by non-activated lymph node cells
Transcripts found in the spinal cord of EAE animals are
expressed in either CNS resident cells or infiltrating leuko-
cytes. As an approximation to focus on the subset of tran-
scripts derived from CNS resident cells and infiltrating
cells "responding" to EAE, genes expressed in lymph node
cells (LNC) were in silico subtracted from the list of genes
expressed in the spinal cords of EAE animals. "Lymph
node transcripts" were compiled by hybridization of
microarrays with RNA from inguinal lymph nodes of five
untreated, healthy DA rats as described above.
RealTime-PCRs
The regulation of selected genes was validated by quanti-
tative RealTime-PCR using RNA isolated from rats from a
different experiment as those sacrificed for microarray
hybridization. RNA samples were reverse transcribed with
random hexamer primers using the Reverse Transcription
System (Promega). RealTime-PCRs were performed with
the Mx3005P Cycler (Stratagene) and the QuantiTect
SYBR GreenPCR-Kit (Qiagen). RealTime-PCRs were done
in triplicate preparations. RealTime-PCR primers are listed
in Table 1. Missing primers were purchased from Qiagen
(QuantiTect-primer assays, Gene Globe database, Qia-
gen). The quantity of each transcript was correlated to the
Table 1: Primer sequences used for RealTime-PCR
Gene Sense Antisense
SLPI TCC CAT TCG TGG ACC AGT GAA GAA TGC CAT CAC ACT GGC CGT CAT TCT
MOG TAC AAC TGG CTG CAC CGA AGA CT AGG CTT TCC TTC GCT CCA GGA AGA
DORA GAG ATA TGT GGA AAC AAG TCA TCA GC AAG TCA GCA CAT CTA TGG TCT TCC A
GPNMB AGG ATT CCA TCT ACA ATT GTG ATG GT CCT AGT CCC TCT TTA ATG CCT ACT
BAFF TCC TGC TAC TCC GCT GGC AT GTC GTC TCC GTT CCG TGA AA
CXCL13 TTT TCT GGA CCA AGG CCA AGA GGA GCT TGG GGA GTT GAA GTA
IRF-1 CAA GGA GGA ACC AGA GAT CGA CA TAG AGT TGC CCA GCA GGG TGT C
Lipocalin2 CAA GTG GCC GAC ACT GAC TA GGT GGG AAC AGA GAA AAC GA
HES1 TAC CCC AGC CAG TGT CAA CA TTC ATT TAT TCT TGC CCG GCPage 3 of 20
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(Applied Biosystems).
Determination of cholesterol concentration in spinal cord 
tissue
Proteins and lipids were extracted from spinal cord tissue
by homogenisation of frozen tissues and sonification in
RIPA buffer (150 mM NaCl, 1% (w/v) Igipal, 0.5% (w/v),
Na-deoxycholate, 0.1% (w/v), SDS, 50 mM Tris-HCl, pH
7.5).Protein concentrations were determined (Lowry-
method) and adjusted to 1 mg/ml using RIPA-buffer.
Total cholesterol content was determined by a colorimet-
ric assay (Roche).  
Immunohistochemical analysis of SLPI expression
Rats were transcardially perfused with ice-cold saline fol-
lowed by 4% paraformaldehyde (PFA). Spinal cords were
removed and postfixed in PFA overnight at 4°C. Tissues
were then cryoprotected by 24 h immersion in a 30% (w/
v) sucrose/PBS-solution and cut into 30 μm sections using
a cryostat. Sections were stored at -80°C in cryoprotectant
solution (ethylene glycol, glycerol, 0.1 M phosphate
buffer pH 7.4, 1:1:2 by volume).
Double-labelling immunofluorescence was carried out
using anti-SLPI (1:200, rabbit anti-human SLPI, HyCult
Biotechnology) in combination with either mouse anti-
rat monocytes/macrophages (ED1, 1:250; Chemicon),
sheep anti-von Willebrand Factor (Serotec, 1:1000),
mouse anti-glial fibrillary acidic protein (GFAP, 1:1000;
Chemicon) or mouse anti-neuron specific nuclear protein
(NeuN, 1:1000; Chemicon). Confocal microscopy was
used to determine the cellular localisation of SLPI in spi-
nal cord slices.
Cultivation of adult neural stem cells (NSC)
Neural stem cells were obtained from the subventricular
zone (SVZ) of 4- or 6-week-old male Wistar rats. Animals
were sacrificed, and brains dissected and washed in ice-
cold Dulbecco's PBS (DPBS) containing 4.5 g/L glucose
(DPBS/Glc). The SVZ from six animals were dissected,
washed in 10 ml DPBS/Glc and centrifuged for five min-
utes at 1,600 g at 4°C. Tissue was minced using scissors.
Pieces were washed again and centrifuged at 800 g and the
pellet resuspended in 0.01% (w/v) papain, 0.1% (w/v)
Dispase II (Roche Diagnostics), 0.01% (w/v) DNase I and
12.4 mM manganese sulphate in HBSS (PAA Laborato-
ries). Subsequently the tissue was incubated for 40 min at
RT. Thereafter, the suspension was centrifuged at 4°C for
5 min at 800 g and the pellet washed three times in 10 ml
DMEM/Ham's F-12 medium containing 2 mM L-
glutamine and 100 U/ml penicillin/streptomycin. Cells
were then resuspended in 1 ml growth medium (neuroba-
sal medium containing B27 (Invitrogen), 2 mM L-
glutamine, 100 U/ml penicillin/streptomycin, 20 ng/ml
EGF, 20 ng/ml bFGF and 2 μg/ml heparin). Cells were
seeded in 6-well plates coated with 250 μg/ml poly-L-
ornithine and 5 μg/ml laminin (Sigma Aldrich) at a den-
sity of 25,000 to 100,000 cells/ml and incubated at 37°C
in 5% CO2. Two thirds of the medium volume were
changed weekly [24]. The determination of the purity and
of the differentiation potential of the progenitor cells was
described before [25]
Analysis of neural stem cell proliferation
The proliferation of NSC was assessed with the FITC BrdU
Flow Kit (BD Pharmingen) according to the manufac-
turer's instructions. 10,000 cells/well were seeded into
laminin-coated 24-well plates in growth medium for four
days. After one day the specified amounts of recombinant
SLPI (provided by Amgen, USA) [26] or recombinant
VEGF (R&D Systems) were added. After three days the
cells were pulsed with BrdU (10 μM) for eight hours. The
proportion of the BrdU-positive cells was determined
using the FACSCalibur-Cytometer (BD Biosciences).
Western blot analysis of IκBα degradation
300.000 NSC were incubated in 2 ml neurobasal medium
with 10 ng/ml TNFα (Peprotech) with or without 500 ng/
ml SLPI for the incubated time period. Total protein was
extracted using the M-Per-reagent (Pierce Biotechnology),
separated by SDS-PAGE and blotted onto a nitrocellulose
membrane (Schleicher & Schuell). A mouse anti-IκBα
antibody (Cell Signaling Technology) was used to detect
IκBα and a mouse anti-actin monoclonal antibody (clone
G4.18, Research Diagnostics) for standardisation. The sec-
ondary anti-mouse antibody (Chemicon, USA) was con-
jugated to horseradish peroxidase. Bands were detected
using the Immobilon Western substrate (Millipore).
Assessment of cyclin D1 and HES1 expression in NSC and 
confirmation of the specificity of the effects of SLPI on 
NSC
100,000 NSC/well were seeded onto laminin-coated 6-
well plates in 2 ml growth medium. After one day the
specified amounts of recombinant SLPI, recombinant
VEGF (R&D Systems) or recombinant α1-antitrypsin (α1-
AT, Sigma Aldrich) were added. Three days later the cells
were harvested, RNA was isolated, cDNA generated and
RealTime-PCRs for cyclin D1 were performed with a
QuantiTect-primer assay (Gene Globe, Qiagen). The
expression of HES1 was determined accordingly in SLPI
treated NSC cultures, but the cells were incubated for
additional four days in differentiation medium.
For the confirmation of the specificity of SLPI's effects on
NSC cultures, NSCs were incubated with 200 ng/ml SLPI
for three days as described above with or without 2 μg/ml
rabbit anti-human SLPI-antibodies (HyCult Biotechnol-
ogy). For the evaluation of the specificity of SLPI's effects,Page 4 of 20
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RealTime-PCR.
Analysis of cell differentiation and cell death
Fixed NSCs were cultivated for three days with the speci-
fied amounts of SLPI in growth medium and subse-
quently for seven days in differentiation medium (NB/
B27 medium with 5% FCS). Afterwards, the cells were
washed in TBS buffer and blocked with a TBS-solution
containing 1% bovine serum albumin (BSA) and 0.2%
Teleostean gelatin (fish gelatin buffer (FGB), Sigma). The
same solution was used during the antibody staining.
Fluorochrome-conjugated secondary antibodies were
used for immunodetection. The following antibodies and
final dilutions were used: primary antibodies: rabbit anti-
GFAP 1:1000 (DAKO), rabbit anti-GalC 1:200 (Chemi-
con), mouse anti-βIII-tubulin 1:500 (clone 5G8,
Promega); secondary antibodies: donkey anti-mouse or
anti-rabbit conjugated with Alexa Fluor® 488 (Molecular
Probes). Nuclear counterstaining was performed with 4',
6'-diamidino-2-phenylindole dihydrochloride hydrate
(DAPI, Sigma) at 0.25 μg/ml. Specimens were mounted
on microscope slides. To assess cell death, 50 μg/ml pro-
pidium iodide (PI, Sigma) was added to the culture
medium.
10 randomly selected observation fields, containing 500–
1,000 cells were analysed for cell fate and cell death anal-
ysis. The expression frequency of selected cell type mark-
ers was determined in three independent experiments.
Results
EAE disease courses of selected animals
The intention of the study was to compare the spinal cord
gene expression profile at three different clinical stages of
EAE with the transcriptome of naïve rats. Therefore,
female DA rats immunised with recombinant MOG-pro-
tein were sacrificed during (1) the acute phase of EAE
defined as the first EAE attack leading to a clinical score of
at least three (n = 3, days 11 and 12), (2) the recovery
phase, i.e. the first day at which the rats began to gain
weight after the acute phase (n = 3, days 13 and 14), and
(3) the relapsing phase, i.e. during a second acute exacer-
bation after temporary recovery (n = 4, days 24 and 25)
(Figure 1). In addition three untreated, healthy control
rats were used.
Summary of the clinical courses and cumulative scores of the DA rats chosen for the microarray expression studyFigure 1
Summary of the clinical courses and cumulative scores of the DA rats chosen for the microarray expression study. A) acute 
phase, B) recovery phase, C) relapsing phase, D) cumulative disease scores (area under the curve) of the examined animals.Page 5 of 20
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rats
Affymetrix oligonucleotide microarrays representing the
complete rat genome were used in this study to character-
ise the EAE gene expression profile. 14,754 of the 26,000
probe sets were judged as present in at least 20% of the
samples by the dchip2006 software [17] and were
included in the subsequent analyses.
According to our selection criteria (signal ratio ≥ 2 & p-
value ≤ 0.01) 1,165 significantly regulated probe sets were
identified. During the acute disease phase 499 probe sets
were differentially regulated, during the recovery phase
731 and only 200 in the relapsing phase (Table 2). A prin-
cipal component analysis of the samples revealed that the
hybridization patterns of the rat group sacrificed in the
relapsing phase were more heterogeneous than the other
groups examined (Figure 2). The heterogeneity of patho-
genic events during the relapsing phase may explain the
lower number of genes detected as significantly regulated
in that group.
Due to the limited number of repetition of the microarray
hybridizations, selected microarray data were validated by
quantitative RealTime-PCR using RNA isolated from rats,
not used for microarray hybridization, but with identical
disease course and similar disease scores as those sacri-
ficed for microarray hybridization (disease courses are in
Figure 3). PCR results confirmed that the selected genes
were expressed differentially, as detected by the microar-
rays (Figure 4).
In order to get an estimation of the grade of reliability of
our expression data, we compared them with previously
published expression data from MS samples or murine
EAE. We detected a high number of regulated genes indi-
cating common features of CNS inflammation; e.g.
increased expression of genes associated with antigen
processing [Additional file 1], antigen presentation (Table
3) or of other genes expressed by immune cells [Addi-
tional file 2]. Furthermore we detected a suppression of
myelin gene expression (Table 4). All four gene groups are
regulated in the same manner in MS or in murine EAE
models [4-9]. We also found some upregulated transcripts
whose relevance for the development of autoimmune
inflammation has recently been reported, e.g. the induc-
tion of BAFF and CXCL13 (Figure 4G &4H) [27], jagged1
[28] and arginase 1 [29], respectively. While confirming
the consistency of our data, these results suggest that
many pathological processes of MS are reproduced by all
EAE models studied so far including EAE in the DA rat as
presented here.
Determination of EAE-response CNS genes
Transcripts expressed in the spinal cord of EAE rats are
derived either from CNS-resident cells or from infiltrating
leukocytes. In order to focus on the regulation of genes
expressed by CNS-resident cells and by activated infiltrat-
ing cells ("EAE-response CNS genes"), we subtracted
genes with expression detectable in lymphoid tissue from
the complete list of genes expressed in the spinal cord.
Genes presumably expressed by non-activated infiltrating
leukocytes were identified in parallel experiments by
hybridization of Affymetrix microarrays with RNA from
inguinal lymph nodes of untreated DA rats (n = 5). Sub-
traction resulted in a list of ~1,500 transcripts of  EAE-
response CNS genes expressed in the spinal cord in at least
one of  the examined disease phases. This included 184
transcripts differentially expressed during the disease
course according to the selection criteria (fold change > 2
& p-value < 0.01, Table 5). According to a hierarchical
clustering performed with dchip2006, 29 of  these tran-
scripts showed a marked upregulation during the acute
phase [Additional file 3]. Several among these transcripts,
notably glycoprotein 49B1, alanyl aminopeptidase
(CD13) and lipocalin 2, while not expressed in the lymph
nodes of naïve DA rats, are reportedly associated with var-
ious activated leukocyte populations [30-32]. This indi-
cates that our subtraction algorithm indeed identified
Principal component analysis of the RG U34A hybridizations performed with BRB Array T olsFigure 2
Principal component analysis of the RG U34A hybridizations 
performed with BRB Array Tools. Hybridization patterns 
from healthy rats and from rats in the acute and the recovery 
phase form clusters. This is not the case for hybridization 
patterns from rats in the relapsing phase.Page 6 of 20
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vated lymphoid cells but up-regulated upon activation.
A large group of genes expressed by CNS-resident cells was
suppressed during all examined disease phases. This
included transcripts encoding for ion channel and trans-
porter proteins (e.g., Slc12a2, Slc24a2, Slco1c1 or Cplx1)
and regulators of synaptic transmission (e.g. Gabbr1,
Ache, Syn2, Reep1, Magi2, Snap25 or Sh3gl2). These find-
ings suggest a profound and sustained impairment of neu-
ronal signal transmission during the course of EAE. The
persistent suppression of transcripts for MOG, myelin
basic protein (MBP), myelin-associated oligodendrocytic
basic protein (MAG) and oligodendrocyte-myelin glyco-
protein (OMG) indicates dysfunction or even loss of oli-
godendrocytes, putative primary targets of the immune
response in EAE (Table 4).
Table 2: Quantity of genes regulated in particular disease phase compared to healthy rats. Gene expression profiling was carried out 
using the RG U34 A, B and C microarrays. Regulation was assessed according to defined criteria. All numbered probe sets were 
present in at least 20% of the samples.
acute – healthy recovery – healthy relapsing – healthy
upregulated
2-fold 187 265 66
4-fold 109 91 29
8-fold 92 36 23
downregulated
2-fold 74 245 73
4-fold 33 76 8
8-fold 7 18 1
Summary of the clinical courses and cumulative scores of the DA rats chosen for the RealTime-PCR experimentsFigure 3
Summary of the clinical courses and cumulative scores of the DA rats chosen for the RealTime-PCR experiments. A) acute 
phase, B) recovery phase, C) relapsing phase, D) cumulative disease scores (area under the curve) of the examined animals.Page 7 of 20
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Confirmation of expression values obtained by microarray hybridization with RealTime-PCR values obtained from different 
samples others than those used for microarray hybridization but with comparable disease course (values are always normalised 
to quantity of 18S rRNA and presented + std dev, four animals per group) for following genes: A) HMG-CoA Reductase, B) 
Low density lipoprotein receptor (LDLR), C) Secretory leukocyte protease inhibitor (SLPI), D) MAP1alpha, E) Glycoprotein 
NMB (GPNMB), F) Downregulated by Activation gene (DORA), G) B cell-activating factor (BAFF), H) CXCL13, I) Myelin-oli-
godendrocyte-glycoprotein (MOG), J) Lipocalin 2 and K) Interferon-g regulated-factor-1 (IRF-1). The different disease phase 
were statistically compared using One Way ANOVA analysis of variance (Holm-Sidak method):*:p < 0.05, **: p < 0.01, ***: p < 
0.001.
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Table 3: Expression of genes related to antigen presentation within the spinal cord during the disease course of MOG-induced EAE
Probeset Gene healthy stddev acute stddev remission stddev relapsing stdev
H33922_f_at RT1 class Ib gene 224.7 35.3 1085.7 102.5 382.8 88.0 677.9 350.6
L40362_f_at 242.0 33.1 913.6 141.0 463.3 84.2 523.5 250.4
M11094_g_at 50.0 9.2 182.4 36.4 117.8 13.4 114.7 32.7
M11071_f_at 919.4 157.0 3552.1 547.2 2325.2 649.9 2208.1 612.6
M24026_f_at 381.6 52.5 1476.6 78.8 915.2 135.4 1016.0 408.4
M24324_f_at 420.3 27.9 1904.7 121.0 1016.5 195.5 1277.4 592.5
M31018_f_at 484.4 56.8 2383.8 392.3 1554.6 336.0 1601.8 614.5
M31038_at 30.5 4.2 180.4 36.4 54.4 4.3 139.7 110.0
rc_AA858651_f_at 386.5 82.9 1585.7 203.2 887.5 152.6 982.4 295.6
rc_AA945159_s_at 115.0 69.6 502.1 439.7 667.2 69.0 304.2 271.3
rc_AI103500_f_at 290.1 9.2 2175.2 48.2 513.8 100.9 1069.4 780.4
rc_AI176358_f_at 299.3 20.7 1176.6 270.5 611.3 42.9 733.8 256.9
rc_AI235223_at 213.6 41.4 947.6 95.3 844.3 112.6 714.9 227.9
AF025308_f_at MHC class Ib antigen (RT1.Cl) 127.5 11.9 696.2 190.0 161.7 19.6 413.8 335.9
L40364_f_at MHC class I RT1.O type 149 processed pseudogene 438.8 41.1 1100.0 178.2 577.9 87.3 722.8 470.2
AF029240_at MHC class Ib RT1.S3 21.8 8.6 94.2 23.8 55.2 4.2 35.6 13.9
AF029240_g_at 99.5 9.0 267.9 94.7 185.6 48.2 135.9 50.5
rc_AI235890_s_at 34.1 15.5 228.3 13.5 55.6 21.5 63.6 42.4
AF074608mRNA_f_at MHC class I antigen (RT1.EC2) 186.2 21.9 612.1 93.6 493.7 119.8 496.0 116.0
M64795_f_at MHC class I antigen gene (RT1-u haplotype) 42.1 6.0 322.6 37.7 59.5 13.0 179.8 148.6
rc_AI235223_at RT1 class I, A3 213.6 41.4 947.6 95.3 844.3 112.6 714.9 227.9
X57523_at Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 78.1 11.6 292.0 108.8 88.2 24.2 123.5 44.1
X57523_g_at 21.9 2.9 308.5 105.5 86.4 31.8 66.2 30.7
X63854_at Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 44.8 9.5 125.4 26.0 60.6 1.1 74.5 23.5
rc_AI170268_at Beta-2-microglobulin 738.0 270.5 2559.2 864.8 4295.5 654.1 2487.2 1142.1
K02815_s_at Butyrophilin-like 2 (MHC class II associated) 86.3 2.8 869.9 155.5 485.3 199.1 519.6 306.1
M15562_at MHC class II RT1.u-D-alpha chain mRNA, 3' end 77.3 5.9 1441.2 355.7 1088.1 375.5 765.1 244.6
M15562_g_at 205.6 126.3 4436.1 1998.8 5944.8 1630.7 3230.7 1453.0
Z49761_at Major histocompatibility complex, class II, DM alpha 21.5 10.3 343.5 52.4 96.9 5.7 125.4 66.4
U31598_s_at 95.9 29.7 799.4 114.3 108.6 12.0 266.3 169.8
U31599_at Major histocompatibility complex, class II, DM beta 4.5 1.9 256.8 107.7 22.7 6.6 68.0 63.0
U31599_g_at 9.9 2.5 441.4 69.5 69.1 9.8 156.8 116.4
rc_AI171966_at 42.7 8.0 1233.0 256.7 433.0 94.2 428.3 286.4
X13044_at CD74 antigen (invariant polpypeptide of major 
histocompatibility class II antigen-associated)
89.2 22.8 2866.0 381.1 2330.7 638.0 1867.9 218.7
X13044_g_at 86.5 22.6 3206.0 873.7 3432.7 796.6 2228.7 364.2
X14254cds_g_at 73.3 18.6 1947.4 288.9 1298.5 384.1 1417.0 427.4
X53054_at MHC class II DLA DRB1 beta chain 1.9 0.3 181.8 49.4 99.7 30.8 101.5 28.4
X53054_g_at 40.3 7.2 788.7 134.2 745.6 233.2 556.7 157.9
rc_AI045321_at Class II, major histocompatibility complex, transactivator 41.0 11.6 245.2 38.0 124.3 30.3 61.7 21.0
rc_AI228153_s_at MHC class II antigen RT1.B-1 beta-chain 25.3 5.9 963.5 320.2 720.3 126.6 451.0 228.3
X56596_at 51.0 18.3 1064.2 72.4 400.0 84.6 439.8 208.1
M36151cds_s_at 39.1 6.0 1090.4 348.8 250.9 68.0 554.4 471.8
Table 4: Expression of myelin genes within the spinal cord during the disease course of MOG-induced EAE
probe set Gene healthy stddev acute stddev recovery stddev relapsing stddev
L21995_s_at Myelin oligodendrocytic glycoprotein (MOG) 1082.4 1035.3 263.2 94.2 249.0 86.8 1082.4 236.7
M99485_at 903.9 600.1 237.2 83.0 837.5 119.2 903.9 232.6
K00512_at Myelin basic Protein (MBP) 13969.6 1215.4 4299.6 3490.7 3565.8 1058.6 13969.6 5036.0
rc_AI145512_at 14362.3 1660.6 7131.6 5155.8 15716.6 2812.9 14362.3 1822.9
D28111_at Myelin-associated oligodendrocytic basic Protein 
(MOBP)
2241.1 1428.6 481.0 142.3 989.1 175.2 2241.1 659.3
D28111_g_at 5595.3 2369.3 1488.9 441.9 3420.5 521.4 5595.3 819.3
M22357_at Myelin-associated glycoprotein (MAG) 294.1 130.8 142.0 26.3 133.4 16.7 294.1 65.4
M22357_g_at 2076.6 1079.9 922.9 146.0 1314.2 296.9 2076.6 251.1
M25888_at Proteolipid Protein (PLP) 6608.0 2018.9 2179.8 3490.7 7643.4 1983.5 6608.0 762.7
rc_AI070277_s_at 9475.6 1072.8 2179.8 679.7 6841.0 963.3 9475.6 1407.0
rc_AI072770_s_at 5556.7 1923.6 1176.3 515.1 2646.7 183.7 5556.7 2321.2
rc_AA964584_at Oligodendrocyte myelin glycoprotein (Omg) 765.4 185.1 210.8 132.7 680.3 47.4 765.4 195.1
L16532_at 2'-3'-cyclic nucleotide Phosphodiesterase 1 (CNP) 4482.2 2061.3 1168.1 305.5 3147.5 391.2 4482.2 2408.6
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in the acute phase suggests a potential contribution to
repair processes [4]. Twelve CNS-specific genes showed
this expression profile (Table 6). Some of these genes had
been described to be involved in repair or regenerative
processes within the CNS before (Map2c (Microtubule-
associated protein 2) [33], Id4 (Inhibitor of DNA binding
4) [34], Ednrb (Endothelin receptor B) [35], Cdh22 (Cad-
herin 22) [36] and Glrx2 (Glutaredoxin 2) [37]. Interest-
ingly, however, the angiogenic growth factor Pdgfd
(Platelet-derived growth factor D (also called spinal cord-
derived growth factor B)) [38], Pnlip (Pancreatic lipase),
the cytokinesis controlling armadillo protein Pkp4 (Pla-
kophilin 4) [39], the peroxysome regulator Pex11a (Per-
oxisome biogenesis factor 11a) [40] and Hoxb8
(Homeobox B8) have not been associated with repair
processes in the CNS yet. Two transcripts of this group are
not yet defined (Genbank accession: AI070489 and
AI229198).
The cholesterol biosynthesis pathway in EAE
Cholesterol is an essential component of eukaryotic
plasma membranes and represents around 30% of the
lipid content within the CNS. In the mature CNS, the
highest cholesterol content can be found in oligodendro-
cyte myelin. Cholesterol availability in oligodendrocytes
is rate-limiting for myelination [41].
Interestingly, our data revealed a suppression of many
genes associated with the cholesterol biosynthesis path-
way throughout the acute, recovery and relapse time
points (Figure 5A, Table 7). This suppression included
HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase
catalysing the rate limiting step in cholesterol biosynthe-
sis (Figure 4A).
A comparable general decrease of the expression of cho-
lesterol transport proteins was not noticed (Table 8).
Rather, apolipoprotein C I (ApoC1) and CD36 were
strongly upregulated during the acute disease phase. The
expression profile and the known expression pattern of
CD36 suggest that its upregulation is probably caused by
Table 5: Numbers of "EAE-response CNS genes" regulated in particular disease phase compared to healthy rats. Differentially 
regulated genes were considered to be "EAE-response CNS genes", when they were not expressed in lymph nodes (based on own 
microarray experiments).
acute – healthy recovery – healthy relapsing – healthy
upregulated
2-fold 8 21 6
4-fold 8 5 2
8-fold 3 3 0
downregulated
2-fold 42 59 34
4-fold 20 15 2
8-fold 7 4 1
Table 6: "EAE-response CNS transcripts" associated with the recovery phase and possibly contributing to repair processes. Summary 
of the ratios of the expression values of the genes in the particular disease phase and healthy rats. For all genes, the differences 
between any disease phase and healthy rats are statistically significant according to the defined selection criteria
Probe set Gene Title acute/healthy recovery/healthy relapsing/healthy
rc_AI229198_at Transcribed locus 0.15 1.88 1.05
rc_AI237207_at Inhibitor of DNA binding 4 0.22 3.23 0.93
X17682_s_at microtubule-associated protein 2 0.38 1.73 0.98
rc_AI070489_at Transcribed locus 0.48 2.69 0.84
X57764_s_at endothelin receptor type B 0.54 3.41 1.40
AA848702_at Platelet-derived growth factor, D 0.54 2.11 0.97
rc_AI101014_at Glutaredoxin 2 (thioltransferase) 0.59 2.28 1.20
S65355_at endothelin receptor type B 0.62 3.89 1.59
M58369_at pancreatic lipase 0.80 5.10 3.84
rc_AA892296_at homeo box B8 (mapped) 0.81 2.14 1.29
rc_AA892128_at peroxisomal biogenesis factor 11A 0.96 2.01 1.38
rc_AA957117_at Cadherin 22 1.09 2.99 1.44
rc_AA964481_at Plakophilin 4 1.18 2.22 1.45Page 10 of 20
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the spinal cord during the acute phase. The expression of
the cholesterol carrier apolipoprotein E (ApoE) was
increased during the recovery disease phase. The only cho-
lesterol transport genes showing a comparable expression
decrease during EAE as the genes of the cholesterol bio-
synthesis were the Glutamate oxaloacetate transaminase
2, the Low density lipoprotein receptor (LDLR, Figure 4B)
and the Oxysterol binding protein-like proteins 1A and 9.
As the transcription of the HMG-CoA reductase or LDLR
is inhibited by the presence of cholesterol derivatives, we
assessed the total cholesterol concentration in the spinal
cord tissue and detected no change of the cholesterol con-
centration at any time point of EAE (Figure 5B). Hence,
the downregulation of the expression of the enzymes of
the cholesterol biosynthesis pathway was not associated
with a corresponding decrease of cholesterol concentra-
tion (Table 8).
SLPI in MOG-induced EAE of DA rats
The expression of the secretory leukocyte protease inhibi-
tor (SLPI) was approximately 100-fold upregulated dur-
ing the acute disease phase and more than 10-fold during
the recovery and relapsing phases (Figure 4C). Immuno-
histochemical analyses of spinal cord slices from rats suf-
fering from acute EAE showed a strong SLPI staining
restricted to the inflammatory infiltrates. During the
relapsing phase the expression pattern of SLPI was more
scattered and therefore less associated with inflammatory
infiltrates (Figure 6). In spinal cord slices from rats sacri-
ficed during the recovery phase only background staining
was seen.
To characterise the cell types expressing SLPI in the CNS,
we also performed immunohistochemical studies. During
the acute phase of EAE cells SLPI staining mostly colocal-
ised with ED1-positive cells, i.e. macrophages and acti-
vated microglia within inflammatory infiltrates (Figure
7). In the recovery phase, we additionally detected SLPI in
a high proportion of GFAP-positive astrocytes as well as in
sporadic NeuN positive neurons (Figure 7). We did not
see costaining with the endothelial cell marker von-Wille-
brand-factor at any time point.
To determine whether the increased SLPI expression
within the spinal cord might contribute to regenerative
processes, we incubated multipotent neural stem cells
(NSCs) from the subventricular zone of adult Wistar rats
[25] for up to seven days in growth medium with varying
amounts of SLPI. This resulted in a reproducible augmen-
tation of cell proliferation by more than 100%, quantified
by both cell counting and determination of BrdU-positive
cells. SLPI-mediated enhancement of proliferation was
similar to the well established effect of VEGF on prolifer-
ation [42] (Figure 8A). As SLPI has been reported to
induce the cell cycle regulator cyclin D1 [43], we assessed
its expression in NSC treated with SLPI by RealTime-PCR.
Indeed, we found cyclin D1 upregulation in parallel and
concomitant with the increase of proliferation when NSC
were incubated with 0.5 to 1 μg/ml SLPI (Figure 8B). SLPI
antibodies could prevent the cyclin D1 induction caused
by recombinant SLPI confirming the specificity of the
effects of recombinant SLPI (Figure 9).
Downregulation of the cholesterol biosynthesis pathway dur-ing EAEFi ure 5
Downregulation of the cholesterol biosynthesis path-
way during EAE. A: Summary of the average expression 
values of genes of the cholesterol biosynthesis pathway (± 
std dev). As we only noticed minor differences of the expres-
sion of these genes within the observed disease phases, the 
expression values obtained for the acute, recovery and 
relapsing disease phase were merged to one value represent-
ing the average expression of the particular gene during EAE. 
All values are correlated to the expression values of the cor-
responding gene in the spinal cord of healthy rats. The EAE 
gene expression was compared to the expression within 
healthy rats using a paired t test. *: p < 0.05. B: Average cho-
lesterol concentration in spinal cord extracts. Rats from dis-
tinct disease phase were sacrificed, their spinal cord 
dissected and lipids and lipoproteins extracted by RIPA 
buffer. Cholesterol concentrations were determined as 
described in Material and Methods.Page 11 of 20
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those of the protease inhibitor α1-antitrypsin (α1-AT).
Some of the features of SLPI are paralleled by α1-AT, e.g. it
induces the hepatocyte growth factor [44] and inhibits the
chemotaxis of neutrophils [45] as well as acute inflamma-
tory responses [46]. Interestingly, α1-AT did not induce
the expression of cyclin D1 (Figure 8C), thereby suggest-
ing that the promotion of cell proliferation cannot only be
attributed to SLPI's protease inhibiting activity.
SLPI inhibits the degradation of IκBα in monocytes
thereby promoting its accumulation within the cell [47].
We observed a reduction of TNFα-induced IκBα degrada-
tion by SLPI in NSC (Figure 10A). By binding to the pro-
moter of the cell differentiation suppressor HES1 (Hairy/
enhancer of split, drosophila, homolog of, 1) IκBα
represses its expression independent of NFκB [48]. We
determined the expression of the Notch-target gene HES1
in NSCs treated again with SLPI and detected a significant
downregulation of HES1 mRNA in the SLPI cultures (Fig-
ure 10B).
As HES1 inhibits the differentiation of NSCs [49], we
finally asked whether SLPI influences the cell fate of the
NSCs. After incubating NSCs for three days with SLPI in
growth medium and another seven days in differentiation
medium, we noticed almost no change of the number of
GFAP expressing astrocytes and of βIII-tubulin expressing
neurons, but a significant dose-dependent increase of oli-
godendrocytes expressing GalC. SLPI did not influence
the survival of NSCs as indicated by a propidium iodide
staining (Figure 11). This implies that the SLPI-mediated
Table 7: Summary of the expression of genes of the cholesterol biosynthesis within the spinal cord during EAE
Affymetrix ID Gene Title Gene Symbol mean healthy mean acute mean recovery mean relapsing
U36992_at cytochrome P450, subfamily 7B, 
polypeptide 1
Cyp7b1 98.59 195.80 276.35 162.86
rc_AI171090_at 3-hydroxy-3-methylglutaryl CoA 
lyase
Hmgcl 202.20 227.46 239.53 261.08
rc_AI171090_g_at 54.98 105.97 67.11 72.45
rc_AA945052_at 102.85 198.26 202.62 199.80
M33648_at 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2
Hmgcs2 138.44 148.71 172.73 176.42
M33648_g_at 53.88 71.08 127.08 89.43
M29472_at mevalonate kinase Mvk 579.91 347.12 365.24 334.64
rc_AA924198_s_at 89.59 30.12 42.34 41.04
D45252_s_at 2,3-oxidosqualene: lanosterol cyclase Lss 133.77 96.43 52.29 62.71
U31352_at 78.55 43.51 25.09 30.56
U53706_at Di-P-Mevalonate Decarboxylase Mvd 337.31 275.95 170.16 249.65
rc_AI236566_at Geranyl-trans-transferase Gtt 539.00 251.35 431.77 336.83
rc_AI180442_at 73.18 30.33 24.05 30.71
M95591_at farnesyl diphosphate farnesyl 
transferase 1
Fdft1 361.69 140.36 10.93 57.25
M95591_g_at 177.78 63.88 14.50 37.18
rc_AA859392_s_at 150.44 60.54 12.54 29.40
rc_AI229016_s_at 683.89 363.56 292.72 350.46
D37920_at squalene monoxidase Sqle 454.41 196.60 217.42 194.23
rc_AA819300_at 106.60 47.75 40.46 44.46
AF003835_at isopentenyl-diphosphate delta 
isomerase
Idi1 358.66 107.23 75.43 70.95
rc_AI236611_at 70.34 40.75 43.74 49.80
M29249cds_at 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase
Hmgcr 88.42 27.52 2.90 10.18
rc_AA924210_at 274.91 136.54 79.63 86.09
X55286_at 29.11 11.75 1.63 5.22
X55286_g_at 49.36 24.45 7.98 12.30
AB016800_at 7-dehydrocholesterol reductase Dhcr7 173.32 60.96 86.66 80.03
AB016800_g_at 179.32 65.09 120.92 104.75
rc_AI177004_s_at 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1
Hmgcs1 741.89 171.63 86.91 96.25
X52625_at 1524.92 577.65 626.34 493.05
rc_AI043855_at sterol-C5-desaturase (fungal ERG3, 
delta-5-desaturase)-like
Sc5d 435.08 141.91 79.75 124.68
AB004096_at cytochrome P450, subfamily 51 Cyp51 246.53 77.01 100.46 87.21Page 12 of 20
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increased survival or decreased cell death.
Discussion
In this study we examined the transcriptional profile of
mRNA isolated from spinal cord tissue of MOG-induced
EAE in DA rats. Comparable approaches have been
adopted in several murine EAE models before (e.g.
[4,6,8,9,18,19,50]). In contrast to prior studies, however,
we selected a chronic rat EAE model for a genome-wide
analysis of the CNS expression profile. We compared the
transcriptomes of the acute, recovery and relapsing phases
of EAE with the transcriptome of untreated, healthy rats
and with each other to detect new EAE-associated genes
and elucidate their relative importance for disease proc-
esses, in particular recovery and repair. More than 1,100
differentially expressed genes were identified. To over-
come the statistical problems caused be the analysis of
only three animals per disease phase, we performed quan-
titative RealTime-PCRs for selected targets using rats
which have not been sacrificed for microarray hybridiza-
tions. Importantly, the microarray data were generally val-
idated by RealTime-PCR.
Table 8: Genes of cholesterol transport proteins being expressed in at least 20% of the samples
Affymetrix ID Gene healthy stdev acute stdev recovery stdev relapsing stdev
M27440_at Apolipoprotein B 49.73 46.6 15.96 4.4 67.62 12.3 70.33 45.3
rc_AA997806_at 53.94 35.0 34.14 14.0 126.63 89.0 50.86 15.7
X15512_at Apolipoprotein C-I 15.92 10.9 415.98 167.1 92.05 18.6 316.06 346.8
X55572_at Apolipoprotein D 2297.39 322.6 1723.52 84.7 1839.49 283.5 2001.28 476.4
X04979_at Apolipoprotein E 2980.67 301.3 5192.22 3005.3 8207.48 1115.9 5531.19 2185.4
rc_AI179131_at ATP-binding cassette, sub-family G, member 1 298.63 46.0 522.68 92.8 362.14 43.9 497.34 188.2
AF063302mRNA#3_s_at Carnitine palmitoyltransferase 1b 83.97 5.2 65.47 18.4 69.39 15.5 81.62 21.0
AF072411_at CD36 antigen 11.01 4.9 180.95 119.4 2.73 0.3 7.13 10.9
AF072411_g_at 27.84 17.9 458.91 256.2 16.00 2.3 26.43 23.7
rc_AA946368_at 25.01 16.7 226.76 62.5 37.79 11.8 20.09 15.0
U23407_at Cellular retinoic acid binding protein 2 45.99 10.2 65.57 39.9 32.39 8.5 53.95 19.5
U89529_at Fatty acid transport protein 347.54 64.0 242.31 9.3 219.71 31.5 275.59 87.1
M18467_at Glutamate oxaloacetate transaminase 2 511.64 35.4 439.99 23.1 259.87 46.9 285.07 47.0
rc_AA892012_g_at 49.39 14.7 50.71 27.6 13.64 9.4 48.43 29.0
L32132_at Lipopolysaccharide binding protein 12.60 4.6 111.01 24.1 40.52 9.4 48.87 25.2
rc_AI043724_at Low density lipoprotein receptor 337.57 35.9 229.21 39.8 166.04 17.8 163.08 36.8
rc_AI070411_at 121.75 44.2 91.50 49.1 7.31 5.7 41.72 24.8
rc_AI070135_at Oxysterol binding protein-like 1A 206.55 78.6 90.59 15.9 80.88 3.6 122.10 54.7
rc_AI070882_at 336.07 149.6 173.52 52.9 208.84 28.7 262.69 76.8
rc_AI137224_at 243.29 43.5 111.30 25.0 107.49 16.8 155.86 52.6
AF040261_s_at phosphatidylcholine transfer protein 26.58 5.9 34.18 2.0 29.38 2.5 30.49 13.4
rc_AA901035_at Oxysterol binding protein-like 6 106.57 7.3 93.54 17.1 105.03 5.6 83.83 14.7
rc_AA944269_at STARD3 N-terminal like 458.93 116.8 363.80 51.7 696.50 62.4 467.24 130.5
rc_AI234872_at Oxysterol binding protein-like 9 262.14 11.2 274.79 70.0 165.72 71.9 191.55 10.3
rc_AI237694_at 32.46 5.4 33.46 11.2 13.17 3.1 21.90 5.1
rc_AI070093_at Oxysterol binding protein-like 5 328.76 41.3 232.18 16.7 228.50 17.1 210.83 67.5
rc_AA892260_g_at Steroidogenic acute regulatory protein 39.59 4.7 70.89 11.8 49.75 4.3 52.25 10.0
M58287_s_at Sterol carrier protein 2, liver 13.39 6.1 9.38 1.1 9.96 1.1 15.50 2.4
M62763complete_seq_at 209.95 25.1 145.84 38.6 171.01 8.9 204.37 52.6
rc_AI171674_at Very low density lipoprotein receptor 89.35 15.8 43.11 15.5 98.31 7.1 89.84 23.9
SLPI protein is expressed in the spinal cord during the acute and the r lap ing ha eFigur 6
SLPI protein is expressed in the spinal cord during 
the acute and the relapsing phase. SLPI-staining of 
longitudinal spinal cord slices obtained from DA rats. 
A: healthy animal, B: acute phase (score 3.5) and C: relaps-
ing phase (score 3.5), (Magnification 50x).Page 13 of 20
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SLPI expression within the spinal cord is associated with ED1-expressing macrophages or activated microglia in the acute phase 
(score 3.5, A) and with GFAP-positive astrocytes (B) and NeuN expressing neuronal cells (C) especially during the relapsing 
phase (score 3.5); there was no association of SLPI with von-Willebrand-factor positive endothelial cells (D). Magnification: 
100x.
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SLPI promotes proliferation of adult neural stem cells and induces cyclin D1Figure 8
SLPI promotes proliferation of adult neural stem cells and induces cyclin D1. A: Proliferation of rat neural stem 
cells after treatment with SLPI or VEGF, respectively. Cells were treated with indicated amounts of SLPI or VEGF for three 
days. Afterwards, they were pulsed with 10 μM BrdU. Proportion of BrdU-positive cells (+ std dev) was determined with the 
FITC BrdU Flow Kit. Presentation of a representative result of three experiments. *:p < 0.05 (according to a One Way 
ANOVA analysis of variance (Holm-Sidak method). B: RealTime-PCR assessment of cyclin D1 expression (n = 3, + std dev) in 
rat adult stem cells after an incubation period of three days with the indicated amounts of SLPI or VEGF, respectively. C: 
Determination of cyclin D1 expression (n = 3, + std dev) of adult neural stem cells treated for three days with indicated 
amounts of SLPI or α1-AT. Presentation of a representative result of three experiments.*:p < 0.05 (according to a One Way 
ANOVA analysis of variance (Holm-Sidak method)).
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confirming data from other EAE-models and providing an
external validation of our analyses, e.g. the upregulation
of genes associated with protein catabolism and antigen
presentation [6,20], the downregulation of oligodendro-
cyte-specific genes [20,51] or of genes involved in synaptic
transmission [4].
By subtracting transcripts of "naïve LNC" in silico from the
total list of regulated genes we were able to focus on "EAE-
response CNS genes". This group includes transcripts dif-
ferentially regulated in CNS-resident cells [4] and genes de
novo induced in populations of activated immigrated leu-
kocytes. As a consequence, this algorithm does not reveal
genes constitutively expressed in LNC and up- or down-
regulated at the time of disease.
We identified 12 genes which were upregulated in the
recovery phase but not during the acute phase. The exclu-
sive expression of a gene during the recovery phase may
implicate a role for the corresponding gene product in
regeneration. Indeed, five among these genes have already
been linked to neuroprotective or repair processes within
the CNS, albeit not in EAE. For example, glutaredoxin 2
protects neuronal cells in vitro from death by excitotoxicity
[37]. The expression of map2c might be associated with
developing neurons and with nerve cell survival during
stress [33]. Id4 is an important factor for neuronal differ-
entiation [34] and has been described as an oligodendro-
cyte differentiation inhibitor during maturation [52]. Id4
might therefore contribute to the block of oligodendro-
cyte differentiation known to be operative in autoim-
mune CNS inflammation. These molecules and of the
other transcripts shown in Table 6 warrant further investi-
gation. Interestingly, plakophilin 4 (p0071) influences
the activity of presenilin 1 [53] that in turn controls the
activity of notch receptors contributing to the inhibition
of the maturation of oligodendroglial progenitor cells in
EAE [54].
The downregulation of virtually all genes of the choles-
terol biosynthesis during lesion evolution of autoimmune
CNS inflammation has not been described previously. So
far, only the suppression of HMG-CoA reductase and of
squalene monooxidase has been reported, occurring in
inflammatory lesions of more than 75% of MS patients
[20]. Of note, the expression of genes involved in extra-
and intracellular transport of cholesterol was not affected
in a similar manner, largely excluding sustained damage
Confirmation of specificity of SLPI's effects on NSCsFigure 9
Confirmation of specificity of SLPI's effects on NSCs. 
Determination of cyclin D1 expression (+ std dev) of adult 
neural stem cells treated for three days with indicated 
amounts of SLPI with or without 2 μg/ml SLPI. *: p < 0.05 
referred to the difference of cyclin D1 expression of cultures 
incubated with or without SLPI antibodies (according to a 
paired t test).
SLPI prevents TNFα-induced IκBα degradation and sup-presses HES1Figure 10
SLPI prevents TNFα-induced IκBα degradation and 
suppresses HES1. A: Western Blot for IκBα with protein 
extracts from neural stem cells stimulated for the indicated 
periods with 10 ng/ml TNFα with (+) or without (-) 500 ng/
ml SLPI. Presentation of one of two experiments. B: Real-
Time-PCR assessment of HES1 expression (n = 3, + std dev) 
in rat adult NSC after an incubation period of three days with 
the indicated amounts of SLPI and consecutive four days in 
differentiation medium. Presentation of a representative 
result of three experiments. *:p < 0.05, **: p < 0.01 (accord-
ing to a One Way ANOVA analysis of variance (Holm-Sidak 
method)).Page 16 of 20
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ings might indicate a feedback inhibition of cholesterol
synthesis, because the overall cholesterol concentration in
the spinal cord remained unchanged during all stages of
EAE. The transcription of many genes of the cholesterol
biosynthesis pathway, including the HMG-CoA Reductase
and LDL receptor is negatively regulated by the presence
of cholesterol or its derivatives [55,56]. Both molecules
have been found to be suppressed in our study. The down-
regulation of the genes of the cholesterol biosynthesis
pathway including the HMG-CoA Reductase might be of
special interest, because HMG-CoA Reductase Inhibitors
(Statins) are assumed to ameliorate the MS disease by
modulating e.g. the activity of T cells and of microglial
cells or by enhancing the survival of oligodendroglial pro-
genitor cells [57].
The secretory leukocyte protease inhibitor (SLPI) is an
11.7 kDa protein originally identified in parotid gland
secretions, in seminal fluid, and in cervical, nasal and
bronchial mucous. Later it was also found in human neu-
trophils, peritoneal macrophages, and in astrocytes and
neurons under ischemic conditions [14]. SLPI has been
recognised as a potent inhibitor of leukocyte serine pro-
teases, including elastase and cathepsin G from neu-
trophils, chymase and tryptase from mast cells, as well as
trypsin and chymotrypsin from pancreatic acinar cells,
respectively [58]. In addition, SLPI suppresses bacterial
growth [59] and inhibits HIV-1 infection of macrophages
[60]. By inhibiting the degradation of IκB, SLPI appears to
exert anti-inflammatory functions on macrophages, neu-
trophils and B cells [15,61]. SLPI reduces inflammatory
gene expression and diminishes inflammatory cell accu-
mulation after hepatic and lung injuries [62,63].
SLPI enhances the differentiation of oligodendroglial cellsFigure 11
SLPI enhances the differentiation of oligodendroglial cells. Differentiation and cell death analysis of NSC treated with 
indicated amounts of SLPI. NSC mounted on microscope slides were cultivated for three days with the specified amounts of 
SLPI in growth medium and subsequently for seven days in differentiation medium. Cells were stained for cell specific markers 
and counted. The shown values are representative for three independent experiments. A: proportion of GFAP positive astro-
glial cells (± std dev), B: proportion of βIII-tubulin positive neuronal cells (± std dev), C: proportion of GalC expressing oli-
godendrocytes (± std dev). *: p < 0.05 (according to a One Way ANOVA analysis of variance (Holm-Sidak method)). D: To 
detect dying cells, 50 μg/ml propidium iodide was added to the culture medium. After ten minutes of incubation. The fraction 
of PI positive cells and the total cell number was determined by counting. Presentation of the proportion of dying cells and 
total cell number (± std dev).Page 17 of 20
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cells [43] and of haematopoietic stem cells [64]. Mice defi-
cient in SLPI show impaired cutaneous wound healing
with increased inflammation and TGF-beta activity, as
well as increased elastase activity [65]. The expression of
SLPI is highly upregulated within ischemic brain tissue,
where it has been ascribed a neuroprotective role, possibly
because of rapid inhibition of activated proteases and its
suppression of inflammatory responses [14].
In this study, microarray and RealTime-PCR analyses
revealed SLPI to be the most strongly induced gene within
the spinal cord during EAE. Using immunohistochemistry
we detected a strong staining for SLPI protein in associa-
tion with perivascular infiltrates. In accordance with find-
ings reported for ischemic brain tissue [14], we detected
SLPI protein in neurons and astrocytes, but found it also
colocalised with markers for activated macrophages or
microglial cells.
We asked whether the SLPI overexpression in the spinal
cord during EAE might support cell renewal in the CNS.
Interestingly, SLPI induced and increased proliferation of
adult NSCs, associated with the selective induction of the
growth-promoting factor cyclin D1. The latter effect is
probably not caused solely by SLPI's inhibitory action on
proteases, because α1-antitrypsin, a comparable protease
inhibitor [46], did not cause a similar upregulation of cyc-
lin D1. Rather, the inhibition of the IκBα degradation by
SLPI [66] and its occupancy of NFκB binding sites [61],
resulting in diminished activity of NFκB, may provide an
explanation for our observation. This hypothesis is further
supported by the inhibition of TNFα-induced IκBα degra-
dation and the suppression of the cell cycle regulator
HES1 in SLPI treated NSC cultures. IκBα suppresses the
expression of HES1 independently of NFκB by binding to
the HES1 promoter [48]. HES1 suppression, however, is
expected to enhance differentiation of neural stem cells
[67].
Interestingly, SLPI treatment promoted dose-dependently
the differentiation of NSCs towards Gal-C expressing oli-
godendrocytes. We did not detect population-specific dif-
ferences in cell survival, thereby excluding a selective
survival advantage of differentiating oligodendrocyte pre-
cursors. The dose-dependency of SLPI's effects have been
described before and explained by opposing effects of
SLPI's direct promoter activity and its inhibition of the
nuclear translocation of NFκB [43,66]. It is rather tempt-
ing to envisage SLPI involved in remyelination by pro-
moting the maturation of progenitor cells towards mature
myelinating cells. Furthermore, by inducing factors like
HGF (hepatocyte growth factor) SLPI might also act as a
chemoattracting factor guiding NSC to the lesions
[44,68]. These questions will be addressed in forthcoming
studies.
Conclusion
We identified novel features of gene expression in the CNS
during EAE, in particular the suppression of genes of cho-
lesterol biosynthesis and a strong upregulation of a gene
not previously associated with autoimmune inflamma-
tion in the CNS but with potential relevance for both con-
trol of inflammation and tissue destruction as well as
promotion of tissue repair. We suggest that SLPI, by pro-
moting the proliferation of adult NSCs and their differen-
tiation towards oligodendroglial cells, may contribute to
repair processes in vivo, expanding its functional spectrum
beyond protease inhibition, prevention of tissue damage
and modulation of inflammation.
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